Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Idaho for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Idaho only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Idaho (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Bartels (NPI 1245492768)

Field	Value
Entity Type	Individual
Organization	David Bartels
Address	3815 N Schreiber Way Unit 101
City	Coeur D Alene
State	ID
ZIP	83815
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 26, 2008

Payer Source	Total Paid
Medicare	$3.5M
Medicaid	$0

Key Findings

This provider is effectively single-payer in the dataset: total Medicare revenue is $3.5M while Medicaid billing is listed as none, so Medicare dominates the revenue picture and Medicaid network exposure in Idaho appears absent. The precomputed statistic that the top 3 Medicare codes by revenue account for 62.8% of this provider's Medicare revenue signals a high concentration of income in a small set of therapies.

Revenue is heavily driven by high-cost oncology biologics: J9299 accounts for $911.7K (26.2% of Medicare revenue), J9271 accounts for $780K (22.4%), and J9144 accounts for $492.5K (14.2%). This code mix indicates the practice’s core service line is infusion oncology and immunotherapy administration rather than primarily office-based procedures.

J9299 is a standout in national benchmarks: it generates $911.7K and ranks #30 of 505 providers nationally (94th percentile) and is characterized as notably above typical national volume, indicating unusually high nivolumab administration relative to peers. Similarly, J0897 (denosumab) generates $369.4K and ranks #273 of 10057 providers nationally (97th percentile), also noted as notably above typical national volume; together these high ranks show concentrated expertise or referral flow for specific injectable therapies.

Multiple chemotherapy administration codes are also high relative to peers, underlining significant infusion throughput: 96413 produced $77.7K and ranks #150 of 7514 providers nationally (98th percentile, notably above typical national volume), 96417 produced $12.6K and ranks in the 97th percentile, and 96367 produced $14.1K and ranks in the 95th percentile. These elevated ranks across infusion/administration codes corroborate that the operation includes routine chemotherapy and multi-drug infusion sessions.

Office evaluation-and-management volumes for established patients are unusually large for this specialty: 99214 produced $137.7K (4.0% of Medicare revenue) and ranks #3512 of 479517 providers nationally (99th percentile; extreme outlier), while 99215 produced $62.1K (1.8%) and ranks #2178 of 145531 providers nationally (98th percentile; extreme outlier). These extreme outlier rankings suggest a high volume of complex outpatient management visits in addition to infusion services, consistent with longitudinal oncology care.

Beyond the top biologics, the practice bills a range of oncology-related J-codes and biosimilars (for example, Q5118 $100.5K; Q5119 $67.2K) and supportive therapies (J1569 $215.6K), indicating a full-service infusion clinic model that pairs drug administration revenue with supportive and diagnostic services. The distribution of revenue toward drug administration codes rather than procedural-only codes underscores reliance on medication administration as the primary revenue engine.

From a business-risk and payer-strategy perspective, the concentration of 62.8% of Medicare revenue in the top three codes creates sensitivity to changes in utilization, reimbursement, or substitution for those specific agents; payers and network managers should note this concentration when evaluating contracting or utilization-management opportunities. The lack of Medicaid billing further means any policy or pricing change at Medicare materially affects the provider’s revenue without offset from state Medicaid volume.

This NPI has longevity in the market (enumerated 2008-06-26, approximately 18 years ago), which, together with the sustained, high-volume coding pattern for specific oncology infusions, points to an established outpatient oncology infusion practice with steady referral or retention patterns rather than a newly emergent operation. Analysts assessing competitive positioning should treat this provider as a mature, infusion-focused Hematology & Oncology physician with marked reliance on a few high-revenue biologics.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

57 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	41,440	$20	$911.7K
J9271	Injection, pembrolizumab, 1 mg	20,000	$40	$780K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	12,960	$40	$492.5K
J0897	Injection, denosumab, 1 mg	20,520	$20	$369.4K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	5,990	$40	$215.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,510	$90	$137.7K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	4,020	$30	$100.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	830	$90	$77.7K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	3,200	$20	$67.2K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	470	$130	$62.1K

Showing 1–10 of 57

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 57 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Idaho Distribution

David Bartels — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Idaho

Full comparison — all codes billed, vs. state median

57 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9299	2	10	41,440	$20	$687.9K
J9144	1	10	12,960	$40	$490.9K
J9271	2	10	12,400	$40	$469.8K
J0129	8	10	9,950	$30	$369.8K
J1569	1	10	5,990	$40	$213.4K
J3490	1	10	230	$880	$174.8K
Q5118	1	10	4,020	$20	$98.8K
J0897	1	30	2,580	$20	$76.2K
Q5119	2	10	3,200	$20	$71.3K
J1454	1	10	120	$340	$39.9K

Showing 1–10 of 57

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Bartels, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Danko Martincic	ID	Hematology & Oncology Physician	$2.6M	$0
Howard Kenney	ID	Rheumatology Physician	$1.2M	$0
Dustin Dinning	ID	Rheumatology Physician	$1.1M	$0
Jonathan Sharrett	ID	Radiation Oncology Physician	$727.8K	$0
Andrew Kominsky	ID	Medical Oncology Physician	$339.1K	$0
Carl Walker	WA	Urology Physician	$209.2K	$0
Ian Udell	MT	Urology Physician	$117.7K	$0
Stephanie Hart	ID	Nurse Practitioner	$10.3K	$0

Nearby Providers

Other providers in the same ZIP code as David Bartels, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Syringa Family Partnership, LLC	ID	Early Intervention Provider Agency	$0	$10.4M
North Star Child Development Center	ID	Clinic/Center	$0	$9.4M
Tesh, Inc.	ID	Developmentally Disabled Services Day Training Agency	$0	$3.5M
Jump Start Pediatric Therapy, LLC	ID	Physical Therapy Clinic/Center	$0	$3.3M
Synergy Healthcare For Kids Inc.	ID	Rehabilitation Clinic/Center	$0	$1.8M
George J Loftus Iii, Dds, LLC	ID	General Practice Dentistry	$0	$1.8M
A Compassionate In-home Care LLC	ID	In Home Supportive Care Agency	$0	$1.6M
Rathdrum Clinic, Inc.	ID	Addiction Medicine (Family Medicine) Physician	$0	$1.1M
Emeritus Corporation	ID	Assisted Living Facility	$0	$739.9K
Empowered Through Play LLC	ID	Mental Health Counselor	$0	$641K

David Bartels — Billing Profile & Reimbursement Data

Sign up for David Bartels — Billing Profile & Reimbursement Data policy alerts

David Bartels — Billing Profile & Reimbursement Data

Sign up for David Bartels — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References